Home › Trial NCT04013880
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Trial IDNCT04013880
- StatusWithdrawn
- PhasePhase 1/2
- Study typeInterventional
- SponsorVanderbilt-Ingram Cancer Center
- Enrollment—
- Start date2019-08-27
- ConditionsAcute Myeloid Leukemia · Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome · Refractory Acute Myeloid Leukemia · Refractory Myelodysplastic Syndrome
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.